Incretins: all 1,182 studies that test it
Page 8 of 12. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.
- Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus SulfonylureaCompletedNCT03125694Phase 3
- Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary SyndromeCompletedNCT03122041Phase 4
- The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without SulphonylureaCompletedNCT03081676Not applicable
- Antidiabetic Effects on Intrahepatic FatCompletedNCT03068065Phase 4
- Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine DepartmentStatus unknownNCT03051243Phase 3
- Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes MellitusWithdrawnNCT03042325Phase 4
- Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS PatientsCompletedNCT03034941Phase 4
- A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or ObeseStatus unknownNCT03018665Phase 4
- Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic CasesCompletedNCT03017352Phase 2
- Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes MellitusStatus unknownNCT03011008Phase 4
- Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.CompletedNCT03007329Phase 4
- Effect of Linagliptin + Metformin vs Metformin Alone in Patients With PrediabetesCompletedNCT03004612Phase 4
- Exenatide and Brown Adipose TissueStatus unknownNCT03002675Phase 4
- Saxenda: Underlying Mechanisms and Clinical OutcomesActive, not recruitingNCT02944500Phase 4
- Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight LossCompletedNCT02941445Phase 4
- Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight MaintenanceCompletedNCT02931383Phase 4
- Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic CardiomyopathyStatus unknownNCT02930265Not applicable
- Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight MaintenanceCompletedNCT02928679Phase 4
- Biomarkers in Obese Patients With Knee Osteoarthritis; Weight MaintenanceCompletedNCT02928614Phase 4
- Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic PatientsCompletedNCT02920801Phase 4
- Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial FatWithdrawnNCT02920190Phase 4
- Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee OsteoarthritisCompletedNCT02910570Phase 4
- Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of ObesityCompletedNCT02909933Phase 4
- Incretin-based Therapy in Early Diagnosed Type 1 DiabetesCompletedNCT02908087Phase 2
- Liraglutide 3 mg for Knee OsteoarthritisCompletedNCT02905864Phase 4
- Evaluation of the Effect of Sitagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 DiabetesStatus unknownNCT02900417Not applicable
- Incretin-based Therapy in Late Preclinical Type 1 DiabetesCompletedNCT02898506Phase 2
- Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DMStatus unknownNCT02887625Not applicable
- HbA1c Variability in Type II DiabetesActive, not recruitingNCT02879409Not applicable
- Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With ObesityCompletedNCT02870231Phase 1
- Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyCompletedNCT02860923Phase 3
- Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)CompletedNCT02857946Phase 1
- Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular GeometryCompletedNCT02851745Phase 3
- Long-acting Exenatide and Cognitive Decline in Dysglycemic PatientsStatus unknownNCT02847403Phase 3
- The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke VolunteersCompletedNCT02838589Phase 2
- Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 DiabetesCompletedNCT02832999Phase 4
- The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in StrokeStatus unknownNCT02829502Phase 2
- CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)CompletedNCT02827890Phase 1
- Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 DiabetesWithdrawnNCT02811484Phase 4
- The Effect of DPP4 Inhibitor on Vasclular HealingStatus unknownNCT02802644Phase 4
- The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin MonotherapyCompletedNCT02798172Not applicable
- Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMICompletedNCT02794402Phase 2
- The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 InhibitorsCompletedNCT02792400Not applicable
- Effect of Liraglutide on Clock GenesStatus unknownNCT02783196Not applicable
- The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End ProductsWithdrawnNCT02768220Phase 4
- An Extension Study of PEAK TrialTerminatedNCT02763007Phase 4
- Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) SecretionCompletedNCT02749032Phase 1
- Liraglutide for HIV-associated Neurocognitive DisorderTerminatedNCT02743598Phase 4
- Drug Transporter Interaction Study PHENTRA_2015_KPUKCompletedNCT02743260Phase 4
- Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic UlcersStatus unknownNCT02742233Phase 4
- Exenatide and Impaired Hypoglycaemic Awareness in Type 1 DiabetesCompletedNCT02735031Phase 2/3
- GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in HumansCompletedNCT02731664Phase 1
- Incretin Axis in Type 1 Diabetes MellitusStatus unknownNCT02725502Not applicable
- Effect of Liraglutide on Fatty Liver Content and Lipoprotein MetabolismTerminatedNCT02721888Phase 4
- Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in HumansStatus unknownNCT02718950Phase 3
- A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.CompletedNCT02717858Phase 1
- A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 YearsCompletedNCT02696148Phase 1
- Gut Hormones in Obesity, Nicotine and Alcohol DependenceStatus unknownNCT02690987Early Phase 1
- Effect of Exenatide on 24h-UAER in Patients With Diabetic NephropathyCompletedNCT02690883Phase 4
- Effect of GLP-1 on AngiogenesisCompletedNCT02686177Phase 4
- Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic HypoglycemiaCompletedNCT02685852Phase 1
- Accelerated Wound Healing in Diabetic Ulcers by SitagliptinWithdrawnNCT02675335Phase 3
- Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 DiabetesTerminatedNCT02674893Phase 4
- GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryActive, not recruitingNCT02673931Not applicable
- Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian DescentCompletedNCT02660047Phase 4
- Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes PatientsCompletedNCT02655770Phase 4
- Effect of Sitagliptin on Progression of Coronary Intermediate LesionCompletedNCT02655757Phase 4
- TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.CompletedNCT02653209Phase 4
- Effects of GLP-1 on Chronic Heart FailureStatus unknownNCT02650596Not applicable
- Study of the Effects of Intravenous Exenatide on Cardiac RepolarizationCompletedNCT02650479Phase 1
- A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver ResectionCompletedNCT02650427Phase 1
- Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and BloodCompletedNCT02650206Phase 1
- Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes SubjectsCompletedNCT02621489Phase 4
- Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 DiabetesCompletedNCT02617654Phase 2
- Preoperative Condition in Giant Obese PatientsCompletedNCT02616003Phase 4
- Incretin-based Therapy in Preclinical Type 1 Diabetes in AdultsStatus unknownNCT02611232Phase 2
- Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2DCompletedNCT02607410Phase 4
- Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary StenosisCompletedNCT02602600Phase 4
- GLP-1 Effects on Insulin and Glucagon in PTDMCompletedNCT02591849Not applicable
- Diabetes Islet Preservation Immune TreatmentWithdrawnNCT02586831Phase 1/2
- The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying RateStatus unknownNCT02584582Phase 2/3
- Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial FunctionStatus unknownNCT02584075Phase 4
- Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 DiabetesStatus unknownNCT02583438Phase 4
- GLP-1 on Non-ST-Segment Elevation Myocardial InfarctionStatus unknownNCT02577848Not applicable
- Sitagliptin Effects on Arterial Vasculature and Inflammation in ObesityCompletedNCT02576288Phase 2
- Incretin Action in Physiology and DiabetesCompletedNCT02550548Phase 1
- Antiproteinuric Effects of Liraglutide TreatmentCompletedNCT02545738Phase 4
- Treatment of Hypoglycemia Following Gastric Bypass SurgeryCompletedNCT02527993Phase 4
- Phase 1 Bioavailability Study of SYR-322METCompletedNCT02508168Phase 1
- Effects of Glucagon Like Peptide-1 on No-reflowStatus unknownNCT02507128Not applicable
- The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)Status unknownNCT02501850Phase 4
- Effects of Glucagon Like Peptide-1 on Haemodynamic ParametersStatus unknownNCT02490176Not applicable
- Improving Beta Cell Function in Mexican American Women With PrediabetesCompletedNCT02488057Phase 4
- Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary SyndromeCompletedNCT02483299Phase 4
- Saxagliptin and Cardiac Structure and FunctionCompletedNCT02481479Phase 4
- The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell FunctionCompletedNCT02473809Phase 4
- Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy StudyWithdrawnNCT02472717Phase 2
- Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DMCompletedNCT02467920Phase 4
- Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic PatientsStatus unknownNCT02462369Phase 4
- Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 DiabetesCompletedNCT02449603Phase 4